AIPT - スカイライン・メディカル (Precision Therapeutics Inc.)

AIPTのニュース

   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha
   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha
   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha

calendar